serine/threonine kinase Polo-like kinase 4
Showing 1 - 25 of >10,000
Hypertension Trial in Lancaster (Salt loading, Hydrochlorothiazide (HCTZ))
Completed
- Hypertension
- Salt loading
- Hydrochlorothiazide (HCTZ)
-
Lancaster, PennsylvaniaAmish Research Clinics
Mar 23, 2022
Solid Tumor Trial in San Antonio, Tyler, Spokane (TU2218 + Pembrolizumab)
Recruiting
- Solid Tumor
- TU2218 + Pembrolizumab
-
San Antonio, Texas
- +2 more
Mar 26, 2023
Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia Trial in Rochester (Biospecimen
Recruiting
- Recurrent Chronic Myelomonocytic Leukemia
- Refractory Chronic Myelomonocytic Leukemia
- Biospecimen Collection
- +3 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 4, 2023
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem
Recruiting
- Acute Myeloid Leukemia (AML)
- Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
- gilteritinib
- +3 more
-
Cincinnati, Ohio
- +18 more
Jan 20, 2023
Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung
Unknown status
- Non-Small Cell Lung Cancer
- Tissue Collection
-
Lebanon, New HampshireDartmouth-Hitchcock Medical Center
Jan 28, 2021
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal
Recruiting
- Borderline Resectable Pancreatic Adenocarcinoma
- +11 more
- Cobimetinib
- +3 more
-
Portland, OregonOHSU Knight Cancer Institute
Mar 22, 2022
Acute Myeloid Leukemia, MDS, Chronic Myelomonocytic Leukemia Trial in Canada, United States (CFI-400945, Azacitidine,
Recruiting
- Acute Myeloid Leukemia
- +5 more
- CFI-400945
- +2 more
-
Duarte, California
- +7 more
Jul 20, 2022
NSCLC Trial in Worldwide (Sotorasib)
Active, not recruiting
- Non-small Cell Lung Cancer
-
Birmingham, Alabama
- +65 more
Nov 29, 2022
BRAF V600E, Metastatic Colorectal Cancer Trial in China (Encorafenib, Cetuximab, FOLFIRI)
Recruiting
- BRAF V600E
- Metastatic Colorectal Cancer
- Encorafenib
- +2 more
-
Beijing, Beijing, China
- +33 more
Dec 20, 2022
Small-cell Lung Cancer, Small Cell Lung Carcinoma Trial in Pittsburgh (Onvansertib)
Recruiting
- Small-cell Lung Cancer
- Small Cell Lung Carcinoma
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Jul 29, 2022
NSCLC Trial in China (JAB 21822)
Recruiting
- Non-small Cell Lung Cancer
- JAB 21822
-
Beijing, Beijing, China
- +20 more
Sep 26, 2022
NSCLC Trial (Bemcentinib, Pembrolizumab, Pemetrexed)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Bemcentinib
- +3 more
- (no location specified)
Jul 19, 2022
Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma Trial in United States
Active, not recruiting
- Stage III Cutaneous Melanoma AJCC v7
- +2 more
- Computed Tomography
- +3 more
-
Birmingham, Alabama
- +759 more
Aug 18, 2022
Patients With Cyclin-dependent Kinase-like 5 Deficiency Disorder
Recruiting
- Cyclin-Dependent Kinase-Like 5 Deficiency Disorder
- No intervention; observational
-
Norcross, GeorgiaCenter for Rare Neurological Diseases
Oct 20, 2022
Cancer (With or Without Metastasis) Trial in Houston (TSN084)
Recruiting
- Cancer (With or Without Metastasis)
-
Houston, TexasMD Anderson Cancer Center
Apr 22, 2022
Acute Myeloid Leukemia (AML), FMS-like Tyrosine Kinase-3 (FLT3) Mutations Trial in Canada, Japan, United States (gilteritinib)
Approved for marketing
- Acute Myeloid Leukemia (AML)
- FMS-like Tyrosine Kinase-3 (FLT3) Mutations
-
Los Angeles, California
- +38 more
Apr 18, 2021
Leukemia, Monocytic, Acute, Pediatric AML Trial in China (Cladribine, G-CSF, Cytarabine)
Recruiting
- Leukemia, Monocytic, Acute
- Pediatric AML
- Cladribine
- +5 more
-
Foshan, Guangdong, China
- +8 more
Mar 28, 2022
Leukemia, Acute Myeloid (AML) Trial in Worldwide (gilteritinib, LoDAC (Low Dose Cytarabine), Azacitidine)
Active, not recruiting
- Leukemia, Acute Myeloid (AML)
- gilteritinib
- +4 more
-
Birmingham, Alabama
- +125 more
Aug 9, 2022
BRAF V600E Unresectable or Metastatic Melanoma, BRAF V600E Metastatic NSCLC, Melanoma Trial in Guangzhou (Encorafenib)
Completed
- BRAF V600E Unresectable or Metastatic Melanoma
- +2 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Jun 9, 2022
Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL),
Recruiting
- Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL)
- +2 more
- Ponatinib
- +2 more
-
Phoenix, Arizona
- +69 more
Aug 23, 2022
Non Small Cell Lung Cancer, Liquid Biopsy, Tyrosine Kinase Inhibitor Trial in Rotterdam
Recruiting
- Non Small Cell Lung Cancer
- +2 more
-
Rotterdam, NetherlandsErasmus MC
Feb 2, 2022
Low-grade Glioma, Plexiform Neurofibroma, CNS Glioma Trial in Canada (Trametinib)
Active, not recruiting
- Low-grade Glioma
- +2 more
-
Calgary, Alberta, Canada
- +6 more
Oct 25, 2022
Activated PI3K-delta Syndrome, Immunodeficiency Primary Trial in Shanghai (Rapamycin)
Recruiting
- Activated PI3K-delta Syndrome
- Immunodeficiency Primary
-
Shanghai, Shanghai, China
- +1 more
Mar 21, 2022